Concurrent presence of both patient and donor t(14;18) in a follicular lymphoma patient after undergoing allogeneic BMT: implications for minimal residual disease detection post-transplant. Bone Marrow Transplant 2003 May;31(10):947-9
Date
05/16/2003Pubmed ID
12748676DOI
10.1038/sj.bmt.1704039Scopus ID
2-s2.0-0037607364 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
We report the case of a t(14:18)(+) follicular lymphoma (FL) patient in long-term clinical remission after undergoing an allogeneic bone marrow transplantation (allo-BMT) from a human leukocyte antigen (HLA)-identical sibling donor who was the normal healthy carrier of a t(14:18)(+) B cell clone. Using real-time quantitative PCR (RQ-PCR) and gel electrophoresis, we document the temporal disappearance of the patient's t(14:18)(+) clone early post-transplant with the concomitant emergence and long-term persistence of the donor's t(14:18)(+) clone in the patient's peripheral blood. This report indicates that the use of PCR-based techniques to measure minimal residual disease in FL patients post-alloBMT should incorporate pretransplant screening of the donor for t(14;18). Furthermore, it suggests that healthy individuals with t(14:18) need not be excluded as donors for FL patients treated with allo-BMT.
Author List
Rosenblum MD, Drobyski WR, Keever-Taylor C, Chang CCAuthor
William R. Drobyski MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultBone Marrow Transplantation
Chromosomes, Human, Pair 14
Chromosomes, Human, Pair 18
Female
Humans
Living Donors
Lymphoma, Follicular
Neoplasm, Residual
Polymerase Chain Reaction
Translocation, Genetic
